Benzinga · Mar 26, 2026
HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $245
HC Wainwright & Co. analyst Andrew S. Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $230 to $245.
IN
NASDAQ · INSM
Insmed Incorporated
Healthcare · Medical - Pharmaceuticals
$112.58
Up+$0.99 (+0.89%)
Updated Nov 1, 2026, 7:30 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 41.63B
- P/E ratio
- -34.92
- Dividend yield
- 0.00%
- 52-week range
- $90.39 – $212.75
- Volume
- 5.18M
- Avg. volume
- 2.37M
Price performance · INSM
INSM price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
INSM closed at $112.58 after 20 trading sessions, up 8.43% for the selected period.
- Last close
- $112.58
- Period change
- +8.43%
- Period low
- $93.33
- Period high
- $112.58
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $113.60 | $116.37 | $111.9675 | $112.58 | 5.18M |
| Oct 29, 2026 | $110.00 | $114.51 | $103.78 | $111.59 | 11.22M |
| Oct 28, 2026 | $94.01 | $97.915 | $93.86 | $96.98 | 4.65M |
| Oct 27, 2026 | $93.33 | $96.37 | $92.87 | $94.96 | 3.35M |
| Oct 26, 2026 | $93.44 | $94.34 | $92.96 | $93.33 | 3.38M |
| Oct 23, 2026 | $94.12 | $94.635 | $92.625 | $93.39 | 3.41M |
| Oct 22, 2026 | $93.50 | $95.59 | $93.33 | $95.06 | 3.1M |
| Oct 21, 2026 | $95.08 | $97.09 | $93.80 | $94.04 | 2.97M |
| Oct 20, 2026 | $95.44 | $97.20 | $94.595 | $95.67 | 2.61M |
| Oct 19, 2026 | $96.27 | $97.88 | $94.38 | $95.29 | 2.72M |
| Oct 16, 2026 | $98.70 | $99.00 | $96.05 | $96.27 | 2.4M |
| Oct 15, 2026 | $99.26 | $100.715 | $97.90 | $99.21 | 3.35M |
| Oct 14, 2026 | $97.39 | $98.00 | $95.76 | $97.79 | 2.74M |
| Oct 13, 2026 | $98.18 | $99.73 | $96.54 | $96.79 | 2.16M |
| Oct 12, 2026 | $98.815 | $100.31 | $98.33 | $98.56 | 1.7M |
| Oct 9, 2026 | $100.52 | $101.82 | $99.15 | $100.60 | 2.47M |
| Oct 8, 2026 | $100.66 | $101.055 | $96.68 | $100.48 | 5.25M |
| Oct 7, 2026 | $103.87 | $104.80 | $101.60 | $101.74 | 3.16M |
| Oct 6, 2026 | $103.97 | $107.87 | $101.32 | $105.23 | 3.69M |
| Oct 5, 2026 | $105.50 | $108.75 | $101.65 | $103.83 | 5.4M |
Latest INSM news
The latest Smart Investors Daily articles mentioning INSM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INSM research
Overview
Company profile and research snapshot.
Company profile
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $226.67
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | Overweight | — |
| Oct 12, 2026 | Wolfe Research | Peer Perform | — |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 30, 2026 | Barclays | Overweight | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 26, 2026
Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Yutrepia's initial commercialization impresses, but mounting competitive threats cloud long-term prospects for Liquidia. See why LQDA stock is upgraded to hold.
SeekingAlpha · Mar 25, 2026
Insmed Incorporated (INSM) Shareholder/Analyst Call - Slideshow
2026-03-25. The following slide deck was published by Insmed Incorporated in conjunction with this event.
Yahoo · Mar 25, 2026
Insmed CEO reveals Japan patient population exceeds US market for lung disease
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States. That came directly from CEO Will Lewis in a recent interview. “There are actually more patients in Japan that have this disease than there ... Insmed CEO reveals Japan patient population exceeds US market for lung disease
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
